Jesper Kjerulff

Jesper Kjerulff

Project lead and COO

Role in PharmNovo: Global project lead.

Born: 1965

Education: MSc chemical engineering and PhD biotechology from Technical University of Denmark, BCom from Copenhagen Business School.

Other current appointments: None.

Work experience: Jesper is a very experienced pharma project leader with global experience across EU, US, China, Japan, and rest of world from early- as well as late-stage drug development projects and with significant experience from interactions with regulatory authorities such as EMA, FDA, PMDA, and CFDA.

For almost two decades, Jesper headed numerous global projects and large, global, cross-functional project teams at Lundbeck across the entire value chain and across small molecules and biologics. He was amongst others global project lead on successful development of Brintellix®/Trintellix® from pre-clinical development over phase I, II, and III clinical development and to registration and launch. Trintellix®/Brintellix® is today a globally launched blockbuster.

Holdings: None.

Member of:

Latest news

View all
December 1, 2023

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
October 18, 2023

Phase IIa studies with WCT

Following the successful completion of our phase I study, we are pleased to announce our collaboration with WCT, Worldwide Clinical Trials, as the phase IIa study of our drug candidate PN6047. This partnership underscores our commitment to developing solutions for neuropathic pain. In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep. PN6047 offers a targeted approach to alleviate this condition, aiming to improve the overall pain experience. Insights on its efficacy will aid in designing subsequent phase IIb/III studies.

Read more
October 18, 2023

Meet Jesper Kjerulff, Chief operations officer and Global project lead

In the pharmaceutical development arena, experts like Jesper Kjerulff stand out. As Global project lead and Chief operations officer (COO) of PharmNovo, Jesper Kjerulff is instrumental in propelling the company's groundbreaking project, PN6047, and advancing the field of neuropathic pain management.

Read more
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more